LEKLI sh.p.k makes its CPHI debut in Milan
From 6 to 8 October 2026, Lekli will take part in CPHI Milan at Fiera Milano, marking its first participation as an exhibitor at one of the leading international events for the…
LEKLI sh.p.k Inaugurates New Pharmaceutical Facility, attended by the Prime Minister Edi Rama
LEKLI sh.p.k Inaugurates New Pharmaceutical Facility, attended by the Prime Minister Edi Rama
The pharmaceutical company LEKLI sh.p.k. has officially inaugurated the completion of the first phase of its new, modern manufacturing facility - a strategic investment that significantly enhances the company’s production…
Prime Minister Edi Rama Visits High-Tech Manufacturing Company LEKLI sh.p.k (Radio Televizioni Shqiptar)
Prime Minister Edi Rama Visits High-Tech Manufacturing Company LEKLI sh.p.k (Radio Televizioni Shqiptar)
Lekli sh.p.k had the honor of welcoming the Prime Minister of Albania, Mr. Edi Rama, during his visit to the Tirana Industrial Park. During the visit, the Prime Minister toured…
ANTIKON L (Clobazam) has granted the Marketing Authorization
ANTIKON L (Clobazam) has granted the Marketing Authorization
LEKLI Announces that the National Agency for Medicines and Medical Devices, has granted the Marketing Authorization for Clobazam (ANTIKON L), ANTIKON L belongs to a group of medicines called benzodiazepines.…
CUPROS L (D-penicillamine) has granted the Marketing Authorization
CUPROS L (D-penicillamine) has granted the Marketing Authorization
LEKLI Announces that the National Agency for Medicines and Medical Devices, has granted the Marketing Authorization for D-penicillamine (CUPROS L), CUPROS L belongs to the group of medicines called disease-modifying…
KAHLERMID L® (Lenalidomide) has granted the Marketing Authorization
KAHLERMID L® (Lenalidomide) has granted the Marketing Authorization
LEKLI Announces that the National Agency for Medicines and Medical Devices, has granted the Marketing Authorization for Lenalidomide (KAHLERMID L®), an oral derivative of thalidomide, is an antineoplastic agent exhibiting…
MBROTIR L (Potassium iodide) has granted the Marketing Authorization
MBROTIR L (Potassium iodide) has granted the Marketing Authorization
LEKLI sh.p.k. announced that the National Agency for Medicines and Medical Devices has validated the Marketing Authorization Application (MAA) for Potassium Iodide (MBROTIR L®). The submission was supported by previously…
LEKLI sh.p.k continues to assist pediatricians with essential medications
LEKLI sh.p.k continues to assist pediatricians with essential medications
After several years of research work, our specialized staff was able to produce very important medications in the pediatric field. FORMACIDIN L (spiramicinë 75 000 UI/mL, tretësirë për përdorim nga…
LEKLI sh.p.k completes first stage of OSD & Oral Liquid pharmaceutical production line
LEKLI sh.p.k completes first stage of OSD & Oral Liquid pharmaceutical production line
LEKLI sh.p.k has completed the first stage of establishing the line of human drug production for producing Oral Solid Dosage (OSD) and Oral Liquid Dosage pharmaceutical forms for internal use.…
LEKLI sh.p.k receives positive evaluations from the Minister of Finance
LEKLI sh.p.k receives positive evaluations from the Minister of Finance
The Minister of Finance and Economy, expressed her positive assessments through a post on her official page. Among other things, she writes that: “LEKLI sh.p.k is a pharmaceutical company focused…
LEKLI sh.p.k donates 526,750 (UI) Human Coagulation Factor VIII 250 UI/ 500 U
LEKLI sh.p.k donates 526,750 (UI) Human Coagulation Factor VIII 250 UI/ 500 U
LEKLI sh.p.k donates 526,750 (UI) Human Coagulation Factor VIII 250 UI/ 500 UI to the University Hospital Center “Mother Teresa”, in Tirana, to cover the needs of its patients. “This…
LEKLI sh.p.k successfully passes the inspection for GMP
LEKLI sh.p.k successfully passes the inspection for GMP
LEKLI sh.p.k hereby informs that the Ministry of Health and Social Protection, pursuant to Article 5 of Law No. 105/2014, dated 31.07.2014 "On Drugs and Pharmaceutical Service”, as amended, and…
